Treatment and Relapse of Autoimmune Pancreatitis.
- Author:
Sung Hoon MOON
1
;
Myung Hwan KIM
;
Do Hyun PARK
Author Information
1. Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. mhkim@amc.seoul.kr
- Publication Type:Review
- Keywords:
Autoimmune pancreatitis;
Treatment;
Relapse
- MeSH:
Appointments and Schedules;
Consensus;
Humans;
Pancreatic Neoplasms;
Pancreatitis;
Pancreatitis, Chronic;
Recurrence;
Steroids
- From:Gut and Liver
2008;2(1):1-7
- CountryRepublic of Korea
- Language:English
-
Abstract:
Autoimmune pancreatitis (AIP) is a peculiar type of chronic pancreatitis whose pathogenesis involves autoimmune mechanisms. The steroid responsiveness has a significant impact on the diagnosis of AIP because patients with AIP and pancreatic cancer share many clinical features. This review focuses on the treatment and relapse of AIP. The goal of AIP treatment is remission of symptoms, serology, radiologic changes, or histology, which also applies to relapse. Although it is generally agreed that steroids should be offered to AIP patients with active disease, there is no standardized steroid regimen for AIP and no consensus on the dose and duration of steroid induction and tapering schedule, and optimal duration and dose of maintenance therapy. Obtaining a consensus on the optimal treatment regimen is very important to reducing the relapse rate. In this review, we discuss the treatment regimens used in many centers.
